EHA 2021 | MOMENTUM: momelotinib vs danazol in myelofibrosis
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, gives an update on the Phase III MOMENTUM study which is investigating momelotinib versus danazol in patients with myelofibrosis who have failed JAK inhibition and are transfusion-dependent and anemic. The study aims to improve spleen symptoms and anemia. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Transcript (edited for clarity)
The MOMENTUM study is an important ongoing Phase III study. Currently it’s still accruing but closing to accrual soon. So, if you have patients, certainly consider it in the near term. These are individuals who are symptomatic, they have failed JAK inhibition, and are transfusion-dependent and anemic. And they are being randomized between receiving momelotinib versus danazol, and then will cross over after the period of evaluation...
The MOMENTUM study is an important ongoing Phase III study. Currently it’s still accruing but closing to accrual soon. So, if you have patients, certainly consider it in the near term. These are individuals who are symptomatic, they have failed JAK inhibition, and are transfusion-dependent and anemic. And they are being randomized between receiving momelotinib versus danazol, and then will cross over after the period of evaluation.
The goals are improvements in spleen symptoms and improvements in anemia. And we think that this is an important study, and it also recognizes that our options for these patients that have failed other JAK inhibition is incredibly limited. We’re hopeful that this will be a favorable study and combined with the data from SIMPLIFY-1 and SIMPLIFY-2, hopefully we’ll clear the pathway for momelotinib becoming an important treatment option for patients with myelofibrosis.
Read more...
Disclosures
Ruben Mesa, MD, has participated in a consultancy role with Novartis, Sierra Onc, LaJolla, Pharma and Constellation; and has received research support from Celgene, Incyte, Abbvie, Samus, Genotech, Promedior, CTI and Constellation.
